Logo image of ADN

ADVENT TECHNOLOGIES HOLDINGS (ADN) Stock Fundamental Analysis

USA - NASDAQ:ADN - US00788A2042 - Common Stock

3.12 USD
-0.34 (-9.83%)
Last: 10/17/2025, 2:13:48 PM
Fundamental Rating

1

Overall ADN gets a fundamental rating of 1 out of 10. We evaluated ADN against 93 industry peers in the Electrical Equipment industry. ADN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ADN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADN has reported negative net income.
ADN had a negative operating cash flow in the past year.
In the past 5 years ADN always reported negative net income.
ADN had a negative operating cash flow in each of the past 5 years.
ADN Yearly Net Income VS EBIT VS OCF VS FCFADN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

ADN's Return On Assets of -612.77% is on the low side compared to the rest of the industry. ADN is outperformed by 95.70% of its industry peers.
Industry RankSector Rank
ROA -612.77%
ROE N/A
ROIC N/A
ROA(3y)-266.83%
ROA(5y)-195.57%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADN Yearly ROA, ROE, ROICADN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

ADN's Gross Margin of 54.58% is amongst the best of the industry. ADN outperforms 96.77% of its industry peers.
ADN's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ADN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.39%
GM growth 5Y8.72%
ADN Yearly Profit, Operating, Gross MarginsADN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

0

2. Health

2.1 Basic Checks

ADN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADN has been increased compared to 1 year ago.
Compared to 5 years ago, ADN has more shares outstanding
Compared to 1 year ago, ADN has a worse debt to assets ratio.
ADN Yearly Shares OutstandingADN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ADN Yearly Total Debt VS Total AssetsADN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -60.96, we must say that ADN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -60.96, ADN is doing worse than 93.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -60.96
ROIC/WACCN/A
WACC9.39%
ADN Yearly LT Debt VS Equity VS FCFADN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.05 indicates that ADN may have some problems paying its short term obligations.
ADN has a worse Current ratio (0.05) than 94.62% of its industry peers.
ADN has a Quick Ratio of 0.05. This is a bad value and indicates that ADN is not financially healthy enough and could expect problems in meeting its short term obligations.
ADN's Quick ratio of 0.05 is on the low side compared to the rest of the industry. ADN is outperformed by 94.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
ADN Yearly Current Assets VS Current LiabilitesADN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.98% over the past year.
Looking at the last year, ADN shows a very strong growth in Revenue. The Revenue has grown by 113.28%.
ADN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 39.50% yearly.
EPS 1Y (TTM)57.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.71%
Revenue 1Y (TTM)113.28%
Revenue growth 3Y-22.61%
Revenue growth 5Y39.5%
Sales Q2Q%-87.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year91.56%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADN Yearly Revenue VS EstimatesADN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADN Yearly EPS VS EstimatesADN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADN. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 30.89, which means the current valuation is very expensive for ADN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ADN indicates a somewhat cheap valuation: ADN is cheaper than 68.82% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.85, ADN is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 30.89
ADN Price Earnings VS Forward Price EarningsADN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADN Per share dataADN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

ADN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVENT TECHNOLOGIES HOLDINGS

NASDAQ:ADN (10/17/2025, 2:13:48 PM)

3.12

-0.34 (-9.83%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryElectrical Equipment
Earnings (Last)06-30 2025-06-30/amc
Earnings (Next)10-20 2025-10-20
Inst Owners8%
Inst Owner Change0%
Ins Owners10.33%
Ins Owner Change0%
Market Cap8.33M
Analysts45
Price TargetN/A
Short Float %9.04%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 30.89
P/S 2.54
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.65
EYN/A
EPS(NY)0.1
Fwd EY3.24%
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS1.23
BVpS-11.02
TBVpS-11.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -612.77%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.58%
FCFM N/A
ROA(3y)-266.83%
ROA(5y)-195.57%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.39%
GM growth 5Y8.72%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.55%
Cap/Sales 2.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -60.96
F-Score4
WACC9.39%
ROIC/WACCN/A
Cap/Depr(3y)123.72%
Cap/Depr(5y)228.29%
Cap/Sales(3y)123.53%
Cap/Sales(5y)88.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.71%
EPS Next Y600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)113.28%
Revenue growth 3Y-22.61%
Revenue growth 5Y39.5%
Sales Q2Q%-87.7%
Revenue Next Year91.56%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year760%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y90.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.33%
OCF growth 3YN/A
OCF growth 5YN/A